TRAW
Traws Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.30
+0.96%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.30
From 52W high−89.19%
Volume49463.00
Market cap$4.69M
P/E (TTM)0.4x
P/S (TTM)1.7x
Div yield—
Key dataNov 4, 2026
Open
$0.30
From 52W high
−89.19%
Volume
49463.00
Market cap
$4.69M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
0.4x
RSI (14)
27.8
MomentumView details →
1D Return
+0.96%
YTD Return
−73.04%
SummaryUpdated Jun 1, 2026
Traws Pharma, Inc. (NASDAQ:TRAW) is a clinical-stage biopharmaceutical company that was originally incorporated in 1998 as Onconova Therapeutics, Inc. before rebranding to its current name in April 2024. Headquartered in Newtown, Pennsylvania, the company focuses on developing small molecule oral therapies for two primary areas: respiratory viral diseases including COVID-19 and influenza, and various forms of cancer. As a clinical-stage biotech firm, Traws Pharma does not yet have approved commercial products and is currently advancing multiple drug candidates through various phases of clinical trials.
Similar companies
Latest newsMore news →
Traws Pharma, Inc. agreed to file an SEC registration statement to register the resale of shares issued under its common stock purchase agreement with Roth Principal Investments LLC.12d agoTraws Pharma, Inc. entered into a common stock purchase agreement giving it the right, but not the obligation, to sell up to $50 million of common stock to Roth Principal Investments LLC over 36 months at a 6% discount to VWAP.12d agoTraws Pharma reported its financial results for the quarter ended June 30, 2026, and provided business highlights including updates on its lead clinical programs and its April 2026 financing.82d ago